Poxel SA
7PO
Company Profile
Business description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Contact
259/261 Avenue Jean Jaures
Immeuble le Sunway
Lyon69007
FRAT: +33 437372010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
Consumer caution dents growth, shares look cheap.
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Income opportunities remain beneath the surface.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,078.90 | 124.00 | 1.38% |
| CAC 40 | 8,205.37 | 27.48 | 0.34% |
| DAX 40 | 26,325.01 | 112.66 | -0.43% |
| Dow JONES (US) | 51,523.06 | 1,833.06 | -3.44% |
| FTSE 100 | 10,782.66 | 46.55 | -0.43% |
| HKSE | 24,796.98 | 877.48 | 3.67% |
| NASDAQ | 24,315.00 | 1,421.52 | -5.52% |
| Nikkei 225 | 61,077.90 | 1,110.73 | -1.79% |
| NZX 50 Index | 13,933.25 | 157.72 | -1.12% |
| S&P 500 | 7,353.73 | 334.89 | -4.36% |
| S&P/ASX 200 | 8,950.00 | 115.50 | 1.31% |
| SSE Composite Index | 3,689.91 | 3.74 | 0.10% |